FDA's Device Center Faces New Charge Of Whistleblower Retaliation
This article was originally published in The Gray Sheet
Executive Summary
Federal officials took steps last week to reinstate a recently fired reviewer in FDA's diagnostics office, claiming that agency actions may have violated the Whistleblower Protection Act.
You may also be interested in...
FDA Email Surveillance Generates Court Battle And Image Problem
FDA’s biggest battle could be in the court of public opinion as employees claim the agency targeted and suppressed them based on their viewpoints and conducted intrusive searches and seizures. FDA says the surveillance began after a device industry attorney complained that a firm’s confidential information had been released.
FDA Email Surveillance Generates Court Battle And Image Problem
FDA’s biggest battle could be in the court of public opinion as employees claim the agency targeted and suppressed them based on their viewpoints and conducted intrusive searches and seizures. FDA says the surveillance began after a device industry attorney complained that a firm’s confidential information had been released.
FDA Email Spying: Crisis Experts Say Agency Needs To Tell Its Story Better
OIG has launched an investigation of FDA’s pre-market review process after the Office of Special Counsel concluded that two devices approved over the objection of FDA scientists likely pose imminent risk to public.